Latest Insider Positions

Danziger Asaf is listed as an insider in the following companies: NVCR / NovoCure Limited Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Peers of Danziger Asaf include the following: Ambrogi Michael J., Burkoth William T., DOYLE WILLIAM F, FUTRELL STEVE, GRANOFF MICHAEL D, GROENHUYSEN WILHELMUS CM, JANIS FRANCES, Kirson Eilon D., LAVIGNE LOUIS J JR, Langloss Timothy J., Longsworth Todd Christopher, MYLOD ROBERT J JR, Melnyk Peter M., PHILLIPS CHARLES G III, Palti Yoram, Perlhagen Gert L., Pomona Associates VII, L.P., Pomona Capital VII Fund Investors, L.P., Pomona Capital VII, L.P., Pomona G.P. Holdings LLC, Pomona Secondary Associates VII LLC, VERNON W ANTHONY, Volati Ltd, WFD Ventures Fund II, L.P., Wyss Hansjoerg, . Peers are determined by cross-linking the filings of Danziger Asaf with insider filings of others at the same companies.

Click the link icon to see the full transaction history.

Tran Date
Security Code Shares Post Shares Percent
2018-01-29 NVCR / NovoCure Chief Executive Officer, Director S -13,974 356,790 -3.77 24.0152 -335,588 8,568,383 -3.92
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

Novocure's (NVCR) CEO Asaf Danziger on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good day, ladies and gentlemen, and welcome to the Novocure fourth quarter 2017 earnings results conference call. At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference call is being recorded. (7-0)

NovoCure 2017 Q4 - Results - Earnings Call Slides

2018-02-22 seekingalpha
The following slide deck was published by NovoCure in conjunction with their 2017 Q4 earnings call. (3-0)

The No BS Plan: Week 1 Report

2018-02-20 seekingalpha
This is the first of a continuing series of reports on the actions take by the virtual portfolio, the "No BS plan" (170-0)

More Health Care Catalysts to Watch For by the End of February

2018-02-19 247wallst
Generally speaking, companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But consider that with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (52-0)

JF's Core Biotech Buys Edition 1 Volume 3: 2 New Purchases, Plus Thoughts On Portfolio Management And Performance

2018-02-19 seekingalpha
For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio. (279-0)

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

JF's Core Biotech Buys: Edition 1 Volume 1

2018-02-05 seekingalpha
This is a reboot of a prior series that readers have requested for some time (apologies for taking so long to get back with a solution). (44-1)

Seattle Genetics: A Buy After Brilliant Acquisition

2018-02-03 seekingalpha
Shares have risen by over 75% during the past three years, yet floundered over the past 12 months or so. (130-2)

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

2018-02-02 seekingalpha
I encourage readers to check out my recent blog post which goes into detail regarding changes to Seeking Alpha and consequently to ROTY. (539-1)

ROTY Edition 1 Volume 71: Thoughts On A Juno Buyout, Outperformance Continues And Other Updates

2018-01-19 seekingalpha
A buyout of Juno Therapeutics would likely provide a boost to the biotech sector if it actually occurs. (372-1)